Bradley v Allianz Australia Insurance Ltd

Link copied
Case Copied 26 min read
DETERMINATION OF REVIEW PANEL
CITATION: Bradley v Allianz Australia Insurance Ltd [2021] NSWPICMP 226
CLAIMANT: Lourise Bradley
INSURER:

Allianz Australia Insurance Ltd

REVIEW PANEL: Principal Member John Harris
Dr David Gorman
Dr Shane Moloney
DATE OF DECISION: 1 December 2021
CATCHWORDS: 

MOTOR ACCIDENTS - The claimant suffered from widespread pain and an underlying depressive disorder which was aggravated by a motor vehicle accident; this was a claim for the cost of referral to a Cannabis clinic and for medical cannabis; Held – the proposed treatment was not reasonable and necessary; statements were provided to the parties by the Faculty of Pain Medicine and a clinical memorandum of the Royal Australian and New Zealand College of Psychiatrists which did not support medical cannabis as a form of treatment other than for the terminally ill or as part of a clinical trial; there was a lack of effectiveness of medical cannabis in reducing pain and adverse effects include habituation/addiction, sedation and dizziness; the use of medical cannabis often leads to the use of other more addictive cannabis products such containing THC; those products cause adverse event profiles in cannabis users incusing psychotic symptoms and cognitive impairment; original medical assessment confirmed.

STATEMENT OF REASONS FOR DECISION OF THE REVIEW PANEL IN RELATION TO A MEDICAL ASSESSMENT

Medical Assessment – Recovery and Treatment and Care

Review Panel Assessment of Recovery
Replacement Certificate issued under section 7.23(1) of the Motor Accident Injuries Act 2017

The Review Panel confirms the certificate dated 3 March 2021.

Review Panel Assessment of Treatment and Care and 
Replacement Certificate issued under section 7.23(1) of the Motor Accident Injuries Act 2017

The Review Panel confirms the certificate dated 3 March 2021.

REASONS

Background

  1. Ms Lourise Bradley suffered injury in a motor accident on 4 December 2018 when another vehicle failed to give way and collided into the left side of her vehicle.

  1. The insurer insured the owner and driver of the other motor vehicle for liability to pay Ms Bradley any damages and/or statutory compensation entitlements under the Motor Accident Injuries Act 2017 (the MAI Act).

  1. The issues in dispute are whether a referral for specialist review with Dr Sanjay Nijhawan at the Cannabis Access Clinic and associated prescription cannabis medication will improve the recovery of Ms Bradley and whether this treatment is reasonable and necessary in the circumstances and relates to the motor accident.

  1. Section 7.17 of the MAI Act defines a “medical dispute” to include dispute between the parties about a medical assessment matter.

  2. Pursuant to Schedule 2, clause 2 of the MAI Act, various matters are declared to be a medical assessment matter including whether “any treatment and care provided to the injured person is reasonable and necessary in the circumstances or relates to the injury caused by the motor accident for the purposes of section 3.24” and whether for the purposes of s 3.28 of the MAI Act “treatment and care provided to an injured worker will improve the recovery of the injured person”.

  1. A medical assessment…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Bradley v Allianz Australia Insurance Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2021] NSWPICMP 226
Decision Date

CaseChat Overview and Summary

Bradley sought compensation from Allianz for injuries sustained in a motor vehicle accident. The primary issue was whether the cost of referral to a Cannabis clinic and for medical cannabis treatment was reasonable and necessary. The court examined the expert statements provided by the Faculty of Pain Medicine and the clinical memorandum of the Royal Australian and New Zealand College of Psychiatrists, which did not support the use of medical cannabis except for terminally ill patients or within a clinical trial. The court considered the lack of evidence regarding the effectiveness of medical cannabis in reducing pain, alongside its potential adverse effects, such as habituation, addiction, sedation, and dizziness. Additionally, the court noted the risk of increased use of other cannabis products, leading to more severe adverse events like psychotic symptoms and cognitive impairment.

The court concluded that the proposed treatment was not reasonable and necessary. The original medical assessment was confirmed, and the expert opinions did not support the use of medical cannabis for the claimant's conditions. The claimant's application for the cost of medical cannabis treatment was dismissed.

The court made an order that Bradley take no costs of Allianz.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.